Advertisement
Advertisement
GALT
Galectin Therapeutics Inc.
3.45
USDSponsored
+0.23
+7.14%
Aug 07, 15:59 UTC -4
Closed
After-Market
3.52
+0.06
+1.88%
GALT Earnings Reports
Positive Surprise Ratio
GALT beat 30 of 42 last estimates.
71%
Next Report
Date of Next Report
Aug 17, 2026
Estimate for Q2 26 (Revenue/ EPS)
--
/-$0.09
Implied change from Q1 26 (Revenue/ EPS)
--
/+12.50%
Implied change from Q2 25 (Revenue/ EPS)
--
/-25.00%
Galectin Therapeutics Inc. earnings per share and revenue
On May 15, 2026, GALT reported earnings of -0.08 USD per share (EPS) for Q1 26, missing the estimate of -0.06 USD, resulting in a -30.72% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -7.66% price change (close before vs. close after earnings).
Looking ahead to Q2 26, -- analysts forecast an EPS of -0.09 USD, with revenue projected to reach -- USD, implying an increase of 12.50% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Ardelyx, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.07
Surprise
-18.85%
Collegium Pharmaceutical, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
$1.74
Actual
$1.92
Surprise
+9.75%
Cronos Group Inc. Common Share
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.00
Actual
$0.03
Surprise
0.00%
Ironwood Pharmaceuticals, Inc. - Class A
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.36
Actual
$0.31
Surprise
-14.62%
Relmada Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.20
Actual
-$0.11
Surprise
+45.95%
Organogenesis Holdings Inc. Class A Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.35
Actual
-$0.71
Surprise
-98.88%
Avita Medical, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.29
Actual
-$0.25
Surprise
+14.50%
electroCore, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.43
Actual
-$0.33
Surprise
+23.40%
Definium Therapeutics, Inc. Common Shares
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.55
Actual
-$1.44
Surprise
-158.25%
Amylyx Pharmaceuticals, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.36
Actual
-$0.39
Surprise
-5.95%
FAQ
What were Galectin Therapeutics Inc.'s earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Galectin Therapeutics Inc. reported EPS of -$0.08, missing estimates by -30.72%, and revenue of $0.00, 0% as expectations.
How did the market react to Galectin Therapeutics Inc.'s Q1 2026 earnings?
The stock price moved down -7.66%, changed from $2.35 before the earnings release to $2.17 the day after.
When is Galectin Therapeutics Inc. expected to report next?
The next earning report is scheduled for Aug 17, 2026.
What are the forecasts for Galectin Therapeutics Inc.'s next earnings report?
Based on --
analysts, Galectin Therapeutics Inc. is expected to report EPS of -$0.09 and revenue of -- for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement